NIKKEI 225
38,617.10 -329.83 (-0.85%) HANG SENG
19,195.60 -25.02 (-0.13%) CRUDE OIL
77.12 -0.45 (-0.58%) GOLD FUTURES
2,383.00 -9.90 (-0.41%) DOW
39,671.04 -201.95 (-0.51%) Bitcoin GBP
54,306.20 -824.23 (-1.50%)
NVO Jul 2024 60.000 put
| Previous close | 0.0500 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 0.0900 |
| Strike | 60.00 |
| Expiry date | 2024-07-19 |
| Day's range | 0.0500 - 0.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | 21 |
BenzingaNovo Nordisk's Once-Weekly Insulin Flagged With Risk Of Low Blood Sugar Ahead Of FDA Review
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee is scheduled to meet on May 24 to review Novo Nordisk A/S’s (NYSE:NVO) application seeking approval for a once-weekly insulin icodec. In December 2023, the FDA said that data submitted by Novo Nordisk during the regulatory review is considered to constitute a major amendment to the Biologics License Application (BLA) for insulin icodec. Therefore, the regulatory review is extended by three months to provide time for a full submissio
Barrons.comHims & Hers Is Selling Copycat Weight-Loss Drugs. Here’s How.
A plan by Hims & Hers Health to sell legal copies of Novo Nordisk weight loss drug Wegovy is drawing pushback from the industry, and bringing new attention to an area of concern for public-health officials. Enormous demand has created shortages of Novo’s Wegovy, as well as a competing weight loss injection from Eli Lilly called Zepbound. Both companies are spending billions of dollars to increase their manufacturing capacity, but the availability of the medicines is limited in the U.S., according to the Food and Drug Administration.
BenzingaAustralia Bans Replica Versions Of Popular Weight-Loss Drugs From Novo Nordisk, Eli Lilly On Safety Concerns
Australia announced on Wednesday that it would ban compounded versions of weight-loss drugs like Novo Nordisk A/S’s (NYSE:NVO) Ozempic and Eli Lilly And Co’s (NYSE:LLY) Mounjaro, citing safety concerns. Recently, the Chinese regulatory authority approved Eli Lilly’s diabetes drug, tirzepatide. Health Minister Mark Butler emphasized that these unregulated copies have not undergone rigorous testing, leading to potential patient risks. Related: The Ozempic Diet: Nestle Launches $5 Pizza For Weight
